Our research project at a glance
We try to identify proteins which are important for the response of leukemic cells to therapeutic drugs. We then investigate how these proteins work in these cells, and how they are regulated by the oncogenes responsible of the disease. We focus our studies on proteins which have important functions in cell cycle regulation, as well as in autophagy, a cellular process recently identified as an important pathway of resistance to several therapeutic drugs.
Our general aim is to decipher the mechanisms that link oncogenic signaling, cell cycle regulation, and autophagy. We try to understand how cell signaling pathways activated by oncogenes, in particular mutated tyrosine kinases, regulate key cell cycle actors, like the CDC25A phosphatase or the DNA damage checkpoint kinase CHK1, for instance.
We identify by different approaches new regulatory modifications of these proteins, such as new phosphorylation sites or new transcriptional and post-transcriptional mechanisms of regulation.
We also investigate how autophagy regulates signaling pathways (signalophagy) in cancer cells, more specifically in acute myeloid leukemia subtypes. We estimate in parallel how these cell cycle actors or autophagy impact the response and the resistance of these cancer cells to therapeutic agents.
We finally translate these basic research questions into the identification of potential therapeutic targets in acute myeloid leukemia.
- Cell cycle
- Acute myeloid leukemia
- CDK inhibitor
Labels and networks
Grants and funders
Oncogene, 36 (26), pp. 3781-3788, 2017, ISSN: 1476-5594 (Electronic) 0950-9232 (Linking).
Elife, 6 , 2017, ISSN: 2050-084X (Electronic) 2050-084X (Linking).
[The yin and the yang of autophagy in cancer cells] Journal Article
Med Sci (Paris), 33 (3), pp. 328-334, 2017, ISSN: 1958-5381 (Electronic) 0767-0974 (Linking).
CHK1 as a therapeutic target to bypass chemoresistance in AML Journal Article
Sci Signal, 9 (445), pp. ra90, 2016, ISSN: 1937-9145 (Electronic) 1945-0877 (Linking).
J Pathol, 239 (3), pp. 250-61, 2016, ISSN: 1096-9896 (Electronic) 0022-3417 (Linking).
Blood, 127 (7), pp. 882-92, 2016, ISSN: 1528-0020 (Electronic) 0006-4971 (Linking).
Cell Cycle, 15 (20), pp. 2742-52, 2016, ISSN: 1551-4005 (Electronic) 1551-4005 (Linking).
Oncotarget, 6 (35), pp. 38061-78, 2015, ISSN: 1949-2553 (Electronic) 1949-2553 (Linking).
Mol Cancer Ther, 14 (10), pp. 2364-73, 2015, ISSN: 1538-8514 (Electronic) 1535-7163 (Linking).